Wolfe Research initiated coverage of Merck (MRK) with a Peer Perform rating. The firm said the main sentiment driver for Merck is ...

In the late 1990s, the FDA expressed concerns regarding the diminishing potency of Merck & Co., Inc.’s (NYSE:MRK) mumps ...

Although Merck’s vaccine, like Pfizer’s, is approved for use in people at least 18 years of age, Capvaxive is the only pneumococcal disease vaccine that was specifically made to protect adults ...

Sanofi Pasteur manufactures the DTP antigens used in the vaccine while Merck/MSD provides the Hib and HBV antigens. FDA approval comes almost three years after Vaxelis was registered in the EU ...

Merck’s ongoing pneumococcal vaccine development program is designed to provide options that address the specific needs of different populations, including infants and children, healthy adults ...

Merck also bundles the three paediatric vaccine sales into a single pot, reporting that MMR II, MMRV shot ProQuad and chickenpox vaccine Varivax made $509 million last year. The AI effect in ...

Objectives: To evaluate 1- and 2-dose regimens of a combined measles, mumps, rubella and varicella vaccine (ProQuad, referred to as MMRV) manufactured with a varicella component of increased potency.

Merck (NYSE:MRK) announced Wednesday that its 21-valent pneumococcal vaccine, Capvaxive, approved in the U.S. to prevent pneumonia, generated positive immune responses in a Phase 3 trial for ...

US pharma giant Merck has scrapped two coronavirus vaccine candidates after they failed to produce an adequate immune response in early trials, the company announced Monday. The vaccines were ...

Merck reports Q3 sales of $16.7 billion, up 4% year-over-year, with Keytruda revenue rising 17%. EPS beats estimates; 2024 guidance updated on global demand shifts.